Top Markets
Coin of the day
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Rang in Aktien #32097
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Aktienkurs
$0.21483059
Zuletzt synchronisiert: 2024-05-07
Marktkapitalisierung
$11.13M
Veränderung (1 Tag)
0.34%
Veränderung (1 Jahr)
0.00%
Land
CA
Handel Antibe Therapeutics Inc. (ATE)

Kategorie

Kursverlauf für Antibe Therapeutics Inc. (ATE)
Höchster Schlusskurs: $0.21 am 2024-05-01

Niedrigster Schlusskurs: $5.29 am 2013-06-01
Kursverlauf der Aktie von Antibe Therapeutics Inc. von 2013 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 -64.54%
2023 70.18%
2022 -33.02%
2021 -82.13%
2020 -5.82%
2019 63.59%
2018 69.29%
2017 -9.13%
2016 -2.14%
2015 -69.92%
2014 -18.37%
2013 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$110.69 -15.03%
US
$331.82 -13.05%
US
$90.44 -2.55%
IE
$51.45 -50.08%
US
$90.82 15.99%
US